Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.
Options
BORIS DOI
Publisher DOI
PubMed ID
28343230
Description
Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.
Date of Publication
2017
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Language(s)
en
Contributor(s)
Adler, Dan | |
Barazzone-Argiroffo, Constance | |
Benden, Christian | |
Boehler, Annette | |
Bridevaux, Pierre-Olivier | |
Brutsche, Martin | |
Clarenbach, Christian F | |
Hostettler, Katrin | |
Kleiner-Finger, Rebekka | |
Nicod, Laurent P | |
Soccal, Paola M | |
Tamm, Michael | |
Lazor, Romain |
Additional Credits
Universitätsklinik für Pneumologie
Universitätsklinik für Pneumologie
Series
Respiration
Publisher
Karger
ISSN
0025-7931
Access(Rights)
open.access